AK105 injection

DRUG3 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Advanced Gastric and Gastro-oesophageal Junction AdenocarcinomaAdvanced Hepatocellular Carcinoma (HCC)Unresectable Metastatic Colorectal Cancer

Phase 2

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unresectable Metastatic Colorectal Cancer

Start: 2021-10-08End: 2024-06-30Target: 120Updated: 2021-10-20

Phase 3

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruitingNCT04344158

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Hepatocellular Carcinoma (HCC)

Start: 2020-08-11End: 2026-12-31Target: 648Updated: 2025-02-20

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Start: 2020-05-20End: 2023-12-31Target: 528Updated: 2020-05-13

Related Papers

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

2025-05-0815 citations

Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated results from a phase Ib/II study.

Journal of Clinical Oncology2021-01-201 citations